Be the first person to write a business review for Senesco Technologies Inc.

SEQUENOM, Inc. company was founded in 1994 and is headquartered in San Diego, California with additional offices in Queensland, Australia; Beijing, China; and Newton, Massachusetts. Sequenom, Inc. provides products, services, diagnostic testing, applications, and genetic analysis products that translate genomic science into solutions for biomedical research, translational research, molecular medicine, and agricultural and livestock applications. It offers MassARRAY system, a high performance nucleic acid analysis platform that measures genetic target material and variations. The company offers its MassARRAY system for various DNA/RNA analysis applications, including single nucleotide polymorphism (SNP), genotyping detection of mutations, analysis of copy number variants, and other structural genome variations, as well as quantitative gene expression analysis, quantitative methylation marker analysis, comparative sequence analysis of haploid organisms, SNP discovery, and oligonucleotide quality control. Sequenom also provides the iPLEX multiplexing assay reagents and chips, which permits multiplexed SNP analysis using a similar amount of reagents and chip surface area. In addition, the company engages in the research, development, and the commercialization of various non-invasive molecular diagnostic tests for prenatal genetic disorders and diseases, oncology, and infectious diseases. It offers its products through direct sales and support personnel to clinical research laboratories, bio-agriculture, bio-technology and pharmaceutical companies, academic institutions, and government agencies worldwide. Sequenom has a collaboration agreement with the Immune Tolerance Institute to develop an advanced newborn screening test for severe combined immunodeficiency.

Silence Therapeutics wants to put the kibosh on disease-causing genes. The company, formerly known as SR Pharma, is working in the field of RNA interference (RNAi), a cutting-edge approach to treating disease that involves interfering with, or silencing, targeted genes associated with disease. Its AtuPLEX drug delivery system is designed to work specifically with RNA molecules. Silence Therapeutics acquired fellow RNAi research company Intradigm in 2010, greatly expanding its RNAi program capabilities, which it hopes will make it a more attractive partner to bigger pharmaceutical companies looking to develop products based on that science.

Sino Biopharmaceutical manufactures medicines that combat cardio-cerebral diseases and hepatitis. Incorporated in 2000, Sino markets its products throughout China in the form of volume injections, PVC-free soft bags for intravenous injections, capsules, tablets, powdered medicines, and granulated medicines. It is additionally researching and developing new medicines in the realms of oncology, analgesic, and respiratory treatment. Sino primarily operates through four main subsidiaries: Beijing Tide Pharmaceutical, Jiangsu Chia Tai Tianqing Pharmaceutical, Nanjing Chia Tai Tianqing Pharmaceutical, and Beijing Chia Tai Green Continent Pharmaceutical.

Sinovac Biotech Ltd. is a profitable biopharmaceutical company headquartered in Beijing, China. The Company focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases including hepatitis A, seasonal influenza, H5N1 (bird flu) pandemic influenza and H1N1 influenza. Sinovac received approval in 2009 for its H1N1 influenza vaccine, PANFLU.1 and has commenced fulfilling orders from the Chinese Central Government pursuit to the government stockpiling program. Sinovac was the first company worldwide to receive approval for H1N1 influenza vaccine.

Sirtris Pharmaceuticals can help keep you healthy in your golden years. The biopharmaceutical company focuses on developing drugs for treating ailments of aging. Its trial drug for the treatment of Type 2 Diabetes, which is associated with obesity, provides health benefits similar to calorie restriction without a change in diet. Founded in 2004, the company owns or licenses more than 150 patent applications for sirtuins, a class of enzymes. The activation of sirtuins helps reduce weight gain, as well improve glucose levels and insulin sensitivity. Sirtris filed an IPO in 2007, but was then acquired by GlaxoSmithKline (GSK) the following year.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.